SQLite Web: event_store.db

Update row 22289 in events

seq

Primary key. INTEGER

id

TEXT NOT NULL

kind

TEXT NOT NULL

ts

TEXT NOT NULL

actor

TEXT

subject_entity_ids

TEXT

payload

{"created_at":"2026-04-11T03:10:51.104915+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:511af5b527c8950d","evidence_event_ids":["evt_cb8679606263"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1802768/0001140361-26-014239.txt","as_of":"2026-04-11T03:10:51.104915+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1802768/0001140361-26-014239.txt","company":"Royalty Pharma plc","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1802768/0001140361-26-014239.txt","article_chars":3718,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_4eadfe1c95fb4ea0","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1802768/0001140361-26-014239.txt","content_type":"text/plain","enriched_at":"2026-04-11T09:04:57.673612+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1802768/0001140361-26-014239.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1802768/0001140361-26-014239.txt","source_event_id":"evt_cb8679606263","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"DEF 14A","fp":"a54caf387c0823a8","kind":"sec_filing","published_at":"20260410","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2020-02-06","2020-06-16","2025-05-16","2025 shareholders meeting","2026-04-10"],"entities":[{"asset_class":"equity","name":"Royalty Pharma plc","relevance":"high","symbol":"RPRX","type":"issuer"},{"asset_class":"other","name":"Nasdaq Stock Market LLC","relevance":"medium","symbol":"","type":"exchange"},{"asset_class":"other","name":"Royalty Pharma Holdings Ltd (RPH)","relevance":"medium","symbol":"","type":"subsidiary/holding entity"},{"asset_class":"other","name":"Royalty Pharma Investments 2019 ICAV (RPI)","relevance":"low","symbol":"","type":"subsidiary/holding entity"}],"event_type":"listing","information_gaps":["What specifically changed versus the prior known state is not provided in the supplied text (no prior filing comparison content included).","The provided excerpt does not include the proxy\u2019s agenda items (e.g., director elections, executive compensation, voting proposals) or any new governance/financial guidance details.","No financial metrics, earnings guidance, or quantitative financial implications are included in the provided text beyond business/portfolio descriptions.","The excerpt does not specify the exact SEC filing timestamp; only the filing date is given in the structured context."],"key_facts":["The filing is a Form DEF 14A proxy statement for Royalty Pharma plc.","Royalty Pharma describes itself as the largest buyer of biopharmaceutical royalties and a leading funder of innovation.","The company states its portfolio entitles it to payments based on top-line sales of royalties on more than 35 commercial products and 20 development-stage product candidates.","The company states it was incorporated under the laws of England and Wales on February 6, 2020.","The company states it completed an IPO on June 16, 2020 and began trading on Nasdaq under symbol \u201cRPRX.\u201d","The company states it completed internalization of its formerly external manager on May 16, 2025, after a 2025 shareholder approval with 99.9% of shares voted in favor (as described in the provided text).","The company states it has two classes of voting shares (Class A and Class B), each with one vote per share, voting together as a single class on matters submitted to shareholders except as required by law.","The company states Class B ordinary shares are not publicly traded and are held by private partnerships/holding vehicles (\u201cPrivate Holders\u201d).","The company states Private Holders have a right to exchange indirect/direct interests in Class B ordinary shares of RPH for direct ownership of Class A ordinary shares of Royalty Pharma plc.","The company states RPH is the sole owner of Royalty Pharma Investments 2019 ICAV (RPI)."],"numeric_claims":[{"label":"IPO completion date","value":"2020-06-16"},{"label":"Incorporation date","value":"2020-02-06"},{"label":"Internalization completion date","value":"2025-05-16"},{"label":"Shareholder approval percentage (internalization)","value":"99.9%"}],"primary_claim":"Royalty Pharma plc filed Form DEF 14A (proxy statement).","relevance_score":0.55,"sentiment":"neutral","source_quality":"high","summary":"Royalty Pharma plc (RPRX) filed a DEF 14A proxy statement. The provided text is largely an overview of the company\u2019s business, portfolio, and corporate structure, including prior events such as its IPO and internalization of its manager.","topics":["SEC filing","proxy statement","DEF 14A","corporate structure","biopharmaceutical royalties","portfolio overview","share classes","governance"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form DEF 14A \u00b7 Royalty Pharma plc \u00b7 Filed 20260410","ticker":"RPRX","tickers":["RPRX"],"title":"RPRX filed DEF 14A","url":"https://www.sec.gov/Archives/edgar/data/1802768/0001140361-26-014239.txt"}}

TEXT NOT NULL

source_ref

TEXT

confidence

REAL (default 0.0

dedupe_key

TEXT

episode_id

TEXT

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel